Bio-Path Holdings, Inc. (BPTH) Bundle
A Brief History of Bio-Path Holdings, Inc. (BPTH)
Company Formation
Company Formation
Bio-Path Holdings, Inc. was incorporated in 2013. The company focuses on the development of nucleic acid-based cancer therapies.
Initial Public Offering (IPO)
In 2014, Bio-Path completed its IPO, raising approximately $6.4 million through the sale of 1.6 million shares at an initial price of $4.00 per share.
Acquisition of Technology
In 2016, Bio-Path acquired the rights to its proprietary technology known as DNAbilize. This technology is designed to enhance the delivery of therapeutic drugs directly to cancer cells.
Clinical Trials and Developments
By 2020, the company had initiated several clinical trials, including:
- Phase 1 clinical trial of BP1002 for the treatment of acute myeloid leukemia (AML).
- Phase 1 clinical trial of BP1002 for the treatment of solid tumors.
Financial Performance and Market Position
For the fiscal year ending December 31, 2020, Bio-Path reported:
| Financial Metric | 2020 Value |
|---|---|
| Total Revenue | $0 |
| Net Loss | $(8.6 million) |
| Operating Expenses | $(8.4 million) |
| Cash and Cash Equivalents | $5.3 million |
Recent Developments
In 2021, Bio-Path expanded its research and development activities and raised an additional $7.5 million via a private placement, enhancing its cash position for ongoing trials.
Partnerships and Collaborations
As of 2022, Bio-Path entered into a collaboration with major pharmaceutical companies for the co-development of cancer therapies, aiming to leverage their networks and resources.
Stock Performance
As of October 2023, Bio-Path's stock (BPTH) has seen fluctuations, with a year-to-date low of $0.70 and a high of $5.36. The market capitalization stands at approximately $30 million.
Future Outlook
Bio-Path continues to focus on expanding its clinical trials and exploring additional partnerships to enhance its product pipeline and market presence.
A Who Owns Bio-Path Holdings, Inc. (BPTH)
Shareholder Composition
The ownership of Bio-Path Holdings, Inc. (BPTH) is divided among institutional investors, retail investors, and company insiders. As of the latest available data, the shareholder composition is as follows:
| Owner Type | Percentage Ownership | Number of Shares Owned |
|---|---|---|
| Institutional Investors | 34% | 4,800,000 |
| Retail Investors | 50% | 7,000,000 |
| Insiders | 16% | 2,200,000 |
Major Institutional Investors
Among institutional investors, several key players hold significant stakes in Bio-Path Holdings, Inc. As of the most recent filings, the major institutional shareholders include:
| Institution | Shares Owned | Percentage Ownership |
|---|---|---|
| BlackRock, Inc. | 1,500,000 | 10% |
| Vanguard Group, Inc. | 1,200,000 | 8% |
| Renaissance Technologies LLC | 700,000 | 5% |
| Wellington Management Company, LLP | 600,000 | 4% |
Insider Ownership
Insider ownership plays a significant role in the governance and strategic direction of BPTH. The top insiders holding shares in the company include:
| Name | Position | Shares Owned |
|---|---|---|
| Peter J. B. H. A. Van Klinken | CEO | 800,000 |
| Susan Shalhoub | COO | 600,000 |
| David A. King | CFO | 400,000 |
Recent Developments Affecting Ownership
Recent financial activities and developments can influence the ownership structure of Bio-Path Holdings, Inc. An analysis of recent stock performance shows:
| Metric | Value | Change (%) |
|---|---|---|
| Current Stock Price | $2.50 | +15% |
| Market Capitalization | $35 million | +10% |
| Shares Outstanding | 14,000,000 | N/A |
Conclusion of Ownership Structure
The current ownership structure of Bio-Path Holdings, Inc. features a blend of institutional investors, retail shareholders, and company insiders, with a total of approximately 14 million shares outstanding. This distribution is essential for understanding the governance and financial health of the company.
Bio-Path Holdings, Inc. (BPTH) Mission Statement
Overview
Bio-Path Holdings, Inc. is a publicly traded biotechnology company focused on developing innovative treatments for cancer utilizing its proprietary DNAbilize™ technology platform. The mission of Bio-Path is to provide new therapeutic options for patients with cancer.
Mission Statement
The mission statement of Bio-Path Holdings is: "To develop innovative therapies for cancer patients and improve the quality of life for patients through targeted drug delivery."
Core Values
- Innovation: Commitment to scientific research and development.
- Integrity: Upholding the highest ethical standards in operations.
- Patient-Centricity: Focusing on the needs and wellbeing of patients.
Strategic Goals
- Advance the clinical development of product candidates.
- Expand the DNAbilize™ technology across various oncological applications.
- Enhance collaboration with academic and industry partners.
Financial Overview
As of the latest fiscal year end of 2022, Bio-Path Holdings reported:
| Financial Metric | Amount ($) |
|---|---|
| Total Assets | 10,528,000 |
| Total Liabilities | 3,301,000 |
| Stockholder’s Equity | 7,227,000 |
| Revenue | 0 |
| Net Loss | (8,417,000) |
Recent Developments
In 2023, Bio-Path Holdings initiated clinical trials for its lead candidate, BP1001, aimed at treating acute myeloid leukemia (AML). The funding secured for this phase was approximately $5 million.
Market Position
Bio-Path Holdings trades under the ticker symbol BPTH on the NASDAQ. As of October 2023, the market capitalization of the company was around $31 million.
Key Partnerships
- Collaboration with various research institutions for clinical studies.
- Partnerships aimed at expanding DNAbilize™ technology's applications.
Investments and Funding
The company has raised approximately $20 million in total funding through public and private offerings since its inception in 2012.
Future Outlook
Bio-Path Holdings aims to expand its pipeline and is targeting multiple indications within oncology, with projected clinical milestones set for 2024.
How Bio-Path Holdings, Inc. (BPTH) Works
Company Overview
Company Overview
Bio-Path Holdings, Inc. (BPTH) is a clinical-stage biotechnology company focused on developing and commercializing innovative RNAi (RNA interference) therapeutics for cancer treatment. The company primarily works on proprietary technologies that enable the delivery of RNA molecules to inhibit the expression of disease-related genes.
Business Model
Bio-Path operates under a biotechnology model that focuses on:
- Research and Development (R&D)
- Preclinical and clinical trial phases
- Collaboration with industry partners
- Intellectual property management
Financial Performance
As of the last reported financials in Q2 2023, Bio-Path Holdings, Inc. demonstrated the following key financial data:
| Financial Metric | Amount |
|---|---|
| Revenue | $0 |
| Operating Expenses | $1.5 million |
| Net Loss | $1.5 million |
| Cash and Cash Equivalents | $8.4 million |
| Market Capitalization | $45.32 million |
Research Pipeline
Bio-Path's research focuses on various therapeutic candidates, including:
- BP1001: Targeting acute myeloid leukemia (AML)
- BP1002: Targeting solid tumors
- BP1003: Targeting hematologic malignancies
Collaboration and Partnerships
Bio-Path collaborates with leading research institutions and pharmaceutical companies to enhance its R&D capabilities. Notable partnerships include:
- Collaboration with MD Anderson Cancer Center
- Agreements with various contract research organizations (CROs)
Stock Performance and Market Data
As of October 2023, Bio-Path's stock (BPTH) exhibited the following market performance:
| Stock Metric | Value |
|---|---|
| Current Share Price | $1.23 |
| 52-Week High | $2.20 |
| 52-Week Low | $0.80 |
| Volume (30-day average) | 300,000 shares |
| Short Interest | 2.5 million shares |
Intellectual Property
Bio-Path has a strong intellectual property portfolio, encompassing more than 15 patent families related to its RNAi therapeutics. This includes patents filed in jurisdictions such as the United States, Europe, and Asia.
Clinical Trials
Bio-Path is actively engaged in multiple clinical trials. As of Q3 2023:
- BP1001 is in Phase 2 trials for AML
- BP1002 is in Phase 1 trials for solid tumors
- BP1003 is preparing for its initial Phase 1 trial
Regulatory Pathway
Bio-Path must navigate the regulatory landscape, which involves:
- Filing Investigational New Drug Applications (INDs)
- Obtaining FDA approvals for clinical trials
- Securing marketing approvals post-trials
Future Strategies
Looking ahead, Bio-Path aims to:
- Expand its product pipeline
- Enhance strategic partnerships
- Increase market presence
- Strengthen financial positioning through capital raises or partnerships
How Bio-Path Holdings, Inc. (BPTH) Makes Money
Revenue Generation through Product Development
Bio-Path Holdings, Inc. focuses on developing innovative RNAi-based therapeutics. Their primary product, BP1001, is aimed at treating various forms of cancer. The potential revenue is derived from the successful commercialization of this drug after completing clinical trials.
Clinical Trials and Partnerships
Bio-Path engages in partnerships with pharmaceutical companies and research institutions to enhance their research capabilities. These collaborations often involve financial support, which significantly contributes to their funding.
- In 2021, Bio-Path reported partnership agreements worth approximately $5 million.
- The company successfully raised around $15 million in funding via equity offerings in the same year.
Grants and Funding
Bio-Path has received grants from government entities and non-profit organizations. For instance, in 2020, they secured a grant of $2.5 million from the National Institutes of Health (NIH) for further development of their pipeline projects.
Market Potential and Revenue Projections
The global RNA therapeutics market is projected to reach approximately $15 billion by 2027. Bio-Path aims to capture a share of this growing market through the commercialization of its RNAi-based therapeutics.
Financial Performance Metrics
Bio-Path’s financial statements indicate continuous investment in R&D, essential for long-term revenue generation.
| Year | Revenue ($ millions) | R&D Expenses ($ millions) | Net Loss ($ millions) |
|---|---|---|---|
| 2021 | $0 | $7.4 | -$8.2 |
| 2020 | $0 | $5.6 | -$6.8 |
| 2019 | $0 | $4.3 | -$5.0 |
Licensing Agreements
Bio-Path has the potential to earn revenue through licensing agreements, allowing other companies to access its proprietary technology. These agreements can provide upfront payments as well as royalties on future sales.
Future Developments and Market Strategy
The company is actively working on expanding its product pipeline beyond BP1001, including potential new candidates targeting different malignancies. This strategy aims to diversify income sources and enhance financial sustainability.
Investor Sentiment and Stock Performance
Bio-Path’s stock performance can reflect investor sentiment and future growth potentials.
| Date | Stock Price ($) | Market Capitalization ($ millions) | Volume Traded |
|---|---|---|---|
| October 2023 | $1.57 | $59.5 | 120,000 |
| September 2023 | $1.45 | $55.0 | 150,000 |
| August 2023 | $2.01 | $75.0 | 200,000 |
Conclusion of Financial Overview
Bio-Path Holdings, Inc. is positioned for potential revenue growth through its innovative drug development, strategic partnerships, and pipeline diversification. Continued investment in research and clinical trials is crucial for the company’s financial health moving forward.
Bio-Path Holdings, Inc. (BPTH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support